Befotertinib
CAS No. 1835667-63-4
Befotertinib ( D-0316 )
Catalog No. M28217 CAS No. 1835667-63-4
Befotertinib is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 222 | Get Quote |
|
10MG | 357 | Get Quote |
|
25MG | 597 | Get Quote |
|
50MG | 851 | Get Quote |
|
100MG | 1152 | Get Quote |
|
200MG | Get Quote | Get Quote |
|
500MG | Get Quote | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBefotertinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionBefotertinib is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.
-
DescriptionBefotertinib is an inhibitor of EGFR tyrosine kinase and can be used for studies about EGFR T790M-positive non-small cell lung cancer.
-
SynonymsD-0316
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorCDK2;CDK5
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1835667-63-4
-
Formula Weight567.6
-
Molecular FormulaC29H32F3N7O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC=CC(=O)NC1=CC(NC2=NC=CC(C3=CN(CC(F)(F)F)C4=C3C=CC=C4)=N2)=C(OC)C=C1N(C)CCN(C)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ka?mierczak A, et al. A novel mechanism of non-Aβ component of Alzheimer's disease amyloid (NAC) neurotoxicity. Interplay between p53 protein and cyclin-dependent kinase 5 (Cdk5). Neurochem Int. 2011;58(2):206-214.
molnova catalog
related products
-
Canertinib dihydroch...
A potent, irreversible, orally available pan-ErbB inhibitor for EGFR and ErbB2 with IC50 of 7.5 nM and 9.0 nM in autophosphorylation assay.
-
Lidocaine Hydrochlor...
Lidocaine, an amide local anesthetic, has anti-inflammatory properties in vitro and in vivo.
-
O-Desmethyl gefitini...
O-Desmethyl gefitinib inhibits EGFR (IC50: 36 nM in subcellular assays). In human plasma, O-Desmethyl gefitinib is an active metabolite of Gefitinib.